2
ALL1
International Partnership for Microbicides1
Johnson & JohnsonYear
2
ALL1
20221
2020DEALS // DEV.
2
ALL2
DevelopmentsCountry
2
ALL2
U.S.A2
ALL1
Inapplicable1
ViiV HealthcareTherapeutic Area
2
ALL2
Infections and Infectious DiseasesStudy Phase
2
ALL1
Approved FDF1
Phase IIIDeal Type
2
ALL2
InapplicableProduct Type
2
ALL2
Other Small MoleculeDosage Form
2
ALL2
Vaginal RingLead Product
2
ALL2
DapivirineTarget
2
ALL2
Reverse transcriptaseLead Product(s) : Dapivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The dapivirine ring received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use through EU-M4all procedure, Prequalification from the World Health Organization (WHO), a WHO recommendation for use and ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : Dapivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapivirine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EMA’s human medicines committee has adopted a positive opinion for Dapivirine Vaginal Ring used to reduce the risk of infection with the human immunodeficiency virus type 1 (HIV-1), in combination with safer sex practices when oral pre-exposure prophyl...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : Dapivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable